Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 219

1.

Survival after chemotherapy and/or radiotherapy versus self-expanding metal stent insertion in the setting of inoperable esophageal cancer: a case-control study.

Sgourakis G, Gockel I, Karaliotas C, Moehler M, Schimanski CC, Schmidberger H, Junginger T.

BMC Cancer. 2012 Feb 15;12:70. doi: 10.1186/1471-2407-12-70.

2.

Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.

Liao Z, Zhang Z, Jin J, Ajani JA, Swisher SG, Stevens CW, Ho L, Smythe R, Vaporciyan AA, Putnam JB Jr, Walsh GL, Roth JA, Yao JC, Allen PK, Cox JD, Komaki R.

Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1484-93.

PMID:
15590179
3.

Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.

Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J Jr, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R.

Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):427-36.

PMID:
15380576
4.

The insertion of self expanding metal stents with flexible bronchoscopy under sedation for malignant tracheobronchial stenosis: a single-center retrospective analysis.

McGrath EE, Warriner D, Anderson P.

Arch Bronconeumol. 2012 Feb;48(2):43-8. doi: 10.1016/j.arbres.2011.09.008. Epub 2011 Dec 2. English, Spanish.

5.

Undernutrition is predictive of early mortality after palliative self-expanding metal stent insertion in patients with inoperable or recurrent esophageal cancer.

Lecleire S, Di Fiore F, Antonietti M, Ben Soussan E, Hellot MF, Grigioni S, Déchelotte P, Lerebours E, Michel P, Ducrotté P.

Gastrointest Endosc. 2006 Oct;64(4):479-84. Epub 2006 Jul 26.

PMID:
16996335
6.

Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma.

Hsu FM, Lee JM, Huang PM, Lin CC, Hsu CH, Tsai YC, Lee YC, Chia-Hsien Cheng J.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e593-9. doi: 10.1016/j.ijrobp.2011.04.032. Epub 2011 Jun 12.

PMID:
21658851
7.

Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy.

Zhang Z, Liao Z, Jin J, Ajani J, Chang JY, Jeter M, Guerrero T, Stevens CW, Swisher S, Ho L, Yao J, Allen P, Cox JD, Komaki R.

Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):656-64.

PMID:
15708243
8.

Individualized, multimodal palliative treatment of inoperable esophageal cancer: clinical impact of photodynamic therapy resulting in prolonged survival.

Lindenmann J, Matzi V, Neuboeck N, Anegg U, Baumgartner E, Maier A, Smolle J, Smolle-Juettner FM.

Lasers Surg Med. 2012 Mar;44(3):189-98. doi: 10.1002/lsm.22006. Epub 2012 Feb 14.

PMID:
22334351
9.

Treatment of maxillary sinus carcinoma: a comparison of the 1997 and 1977 American Joint Committee on cancer staging systems.

Le QT, Fu KK, Kaplan M, Terris DJ, Fee WE, Goffinet DR.

Cancer. 1999 Nov 1;86(9):1700-11.

PMID:
10547542
10.

Cervical nodal metastases from occult primary: undifferentiated carcinoma versus squamous cell carcinoma.

Tong CC, Luk MY, Chow SM, Ngan KC, Lau WH.

Head Neck. 2002 Apr;24(4):361-9.

PMID:
11933178
11.

Concurrent chemoradiotherapy or endoscopic stenting for advanced squamous cell carcinoma of esophagus: a case-control study.

Wong SK, Chiu PW, Leung SF, Cheung KY, Chan AC, Au-Yeung AC, Griffith JF, Chung SS, Ng EK.

Ann Surg Oncol. 2008 Feb;15(2):576-82. Epub 2007 Dec 5.

PMID:
18057993
12.

[Effort to radically cure stage III and IV esophageal carcinoma with simultaneous radiotherapy and chemotherapy in standard clinical practice].

Farzad M, De Luca MC, Rubino G, Pirtoli L, Pepi F, Sebaste L, Ponticelli P, Atzeni G, Maranzano E, Silvano G.

Radiol Med. 2001 Jul-Aug;102(1-2):72-7. Italian.

PMID:
11677442
13.

Natural course of inoperable esophageal cancer treated with metallic expandable stents: quality of life and cost-effectiveness analysis.

Xinopoulos D, Dimitroulopoulos D, Moschandrea I, Skordilis P, Bazinis A, Kontis M, Paraskevas I, Kouroumalis E, Paraskevas E.

J Gastroenterol Hepatol. 2004 Dec;19(12):1397-402.

PMID:
15610314
14.

Self-expanding covered metallic stent as a bridge to surgery in esophageal cancer: impact on oncologic outcomes.

Mariette C, Gronnier C, Duhamel A, Mabrut JY, Bail JP, Carrere N, Lefevre JH, Meunier B, Collet D, Piessen G; FREGAT Working Group–FRENCH–AFC; FREGAT Working Group-FRENCH-AFC.

J Am Coll Surg. 2015 Mar;220(3):287-96. doi: 10.1016/j.jamcollsurg.2014.11.028. Epub 2014 Dec 12.

PMID:
25617915
15.

Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma.

Coia LR, Engstrom PF, Paul AR, Stafford PM, Hanks GE.

Int J Radiat Oncol Biol Phys. 1991 Jan;20(1):29-36.

PMID:
1704362
16.

Stents for palliation of obstructive metastatic colon cancer: impact on management and chemotherapy administration.

Karoui M, Charachon A, Delbaldo C, Loriau J, Laurent A, Sobhani I, Tran Van Nhieu J, Delchier JC, Fagniez PL, Piedbois P, Cherqui D.

Arch Surg. 2007 Jul;142(7):619-23; discussion 623.

PMID:
17638798
17.

Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.

Koo DH, Park SI, Kim YH, Kim JH, Jung HY, Lee GH, Choi KD, Song HJ, Song HY, Shin JH, Cho KJ, Yoon DH, Kim SB.

Cancer Chemother Pharmacol. 2012 Mar;69(3):655-63. doi: 10.1007/s00280-011-1750-5. Epub 2011 Oct 4.

PMID:
21968953
18.

Evolving management and outcome of esophageal cancer with airway involvement.

Alexander EP, Trachiotis GD, Lipman TO, Wadleigh RG.

Ann Thorac Surg. 2001 May;71(5):1640-4.

PMID:
11383814
19.

Prior chemoradiotherapy is associated with a higher life-threatening complication rate after palliative insertion of metal stents in patients with oesophageal cancer.

Lecleire S, Di Fiore F, Ben-Soussan E, Antonietti M, Hellot MF, Paillot B, Lerebours E, Ducrotté P, Michel P.

Aliment Pharmacol Ther. 2006 Jun 15;23(12):1693-702.

20.

Outcome of palliative esophageal stenting for malignant dysphagia: a retrospective analysis.

Burstow M, Kelly T, Panchani S, Khan IM, Meek D, Memon B, Memon MA.

Dis Esophagus. 2009;22(6):519-25. doi: 10.1111/j.1442-2050.2009.00948.x. Epub 2009 Mar 6.

PMID:
19302213

Supplemental Content

Support Center